Stock Track | Ascendis Pharma Soars 5.13% in Pre-Market Following Wells Fargo's Buy Rating

Stock Track11-17

Shares of Ascendis Pharma A/S (ASND) are surging 5.13% in pre-market trading on Monday, following a positive analyst report from Wells Fargo. The Danish biopharmaceutical company's stock price jump comes after Wells Fargo reiterated its Buy rating on the company, signaling strong confidence in Ascendis Pharma's future prospects.

In a report released on November 14, Wells Fargo analyst Derek Archila maintained his bullish stance on Ascendis Pharma, setting a price target of $297.00. This target suggests significant upside potential for the stock, likely contributing to the enthusiastic investor response seen in early trading.

The pre-market rally underscores the impact of analyst ratings on investor sentiment, particularly for biopharmaceutical companies like Ascendis Pharma. As the market opens, investors will be watching closely to see if this early momentum continues throughout the trading session. The company's innovative endocrinology rare disease portfolio and potential for growth appear to be key factors driving the positive outlook from Wells Fargo and the subsequent stock price increase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135681185?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 22:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135681185","market":"nz","top_or_hot":-1,"title":"Stock Track | Ascendis Pharma Soars 5.13% in Pre-Market Following Wells Fargo's Buy Rating","media":"Stock Track","content":"<p>Shares of Ascendis Pharma A/S (ASND) are surging 5.13% in pre-market trading on Monday, following a positive analyst report from Wells Fargo. The Danish biopharmaceutical company's stock price jump comes after Wells Fargo reiterated its Buy rating on the company, signaling strong confidence in Ascendis Pharma's future prospects.</p>\n\n<p>In a report released on November 14, Wells Fargo analyst Derek Archila maintained his bullish stance on Ascendis Pharma, setting a price target of $297.00. This target suggests significant upside potential for the stock, likely contributing to the enthusiastic investor response seen in early trading.</p>\n\n<p>The pre-market rally underscores the impact of analyst ratings on investor sentiment, particularly for biopharmaceutical companies like Ascendis Pharma. As the market opens, investors will be watching closely to see if this early momentum continues throughout the trading session. The company's innovative endocrinology rare disease portfolio and potential for growth appear to be key factors driving the positive outlook from Wells Fargo and the subsequent stock price increase.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ascendis Pharma Soars 5.13% in Pre-Market Following Wells Fargo's Buy Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ascendis Pharma Soars 5.13% in Pre-Market Following Wells Fargo's Buy Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-17 22:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Ascendis Pharma A/S (ASND) are surging 5.13% in pre-market trading on Monday, following a positive analyst report from Wells Fargo. The Danish biopharmaceutical company's stock price jump comes after Wells Fargo reiterated its Buy rating on the company, signaling strong confidence in Ascendis Pharma's future prospects.</p>\n\n<p>In a report released on November 14, Wells Fargo analyst Derek Archila maintained his bullish stance on Ascendis Pharma, setting a price target of $297.00. This target suggests significant upside potential for the stock, likely contributing to the enthusiastic investor response seen in early trading.</p>\n\n<p>The pre-market rally underscores the impact of analyst ratings on investor sentiment, particularly for biopharmaceutical companies like Ascendis Pharma. As the market opens, investors will be watching closely to see if this early momentum continues throughout the trading session. The company's innovative endocrinology rare disease portfolio and potential for growth appear to be key factors driving the positive outlook from Wells Fargo and the subsequent stock price increase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ASND","symbol_name":"Ascendis Pharma A/S","start_time":0,"source_url":"","article_id":"1135681185","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135681185","pubTimestamp":1763391152,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Ascendis Pharma A/S (ASND) are surging 5.13% in pre-market trading on Monday, following a positive analyst report from Wells Fargo. The Danish biopharmaceutical company's stock price jump...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ASND":"Ascendis Pharma A/S"},"translate_title":"个股追踪|富国银行买入评级后Ascendis Pharma盘前大涨5.13%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASND":1},"content_text":"Shares of Ascendis Pharma A/S (ASND) are surging 5.13% in pre-market trading on Monday, following a positive analyst report from Wells Fargo. The Danish biopharmaceutical company's stock price jump comes after Wells Fargo reiterated its Buy rating on the company, signaling strong confidence in Ascendis Pharma's future prospects.\nIn a report released on November 14, Wells Fargo analyst Derek Archila maintained his bullish stance on Ascendis Pharma, setting a price target of $297.00. This target suggests significant upside potential for the stock, likely contributing to the enthusiastic investor response seen in early trading.\nThe pre-market rally underscores the impact of analyst ratings on investor sentiment, particularly for biopharmaceutical companies like Ascendis Pharma. As the market opens, investors will be watching closely to see if this early momentum continues throughout the trading session. The company's innovative endocrinology rare disease portfolio and potential for growth appear to be key factors driving the positive outlook from Wells Fargo and the subsequent stock price increase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135681185","isCrawlerRequest":true}